| abstract |
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents 1, n represents 1, Z represents N or C, in particular N; -X1- represents C1-4alkyl, in particular methyl; -X2- represents -C1-4alkyl- or -C1-4alkyl-NR7-, in particular propyl, -ethyl-NR7- or -propyl-NR7-; -Y- represents-NR2-C1-6alkyl-CO-NR4-, -Het1-C1-6alkyl-CO-NR5- or -Het2-CO-NR6- and wherein the -C1-6alkyl- linker of -NR2-C1-6alkyl-CO-NR4- or -Het1-C1-6alkyl-CO-NR5- is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo and phenyl; R1 represents hydrogen, chloro, fluoro or bromo; R2 represents -C1-4alkyl-, in particular ethyl or methyl; R7 represents hydrogen; R8 represents hydrogen; R4, R5 and R6 represent hydrogen; Het1 is selected from piperazinyl or piperidinyl, in particular -piperazinyl; Het2 selected from pyrrolidinyl or piperidinyl, in particular pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy. |